The forecasted number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in Germany remains constant at 98 cases for 2024 through 2026, with a slight increase to 99 cases for 2027 and 2028. The variation between these forecasted years is minimal, indicating a stable trend in the incidence of RR-/MDR-TB.
Regarding future trends, it is essential to closely monitor developments in healthcare policies, advancements in tuberculosis treatment, and any potential emergence of more efficient diagnostic methods, as these factors could significantly impact the resistance patterns and case numbers in the coming years. Focus should also be given to global collaborations aimed at combating this global health challenge, which might influence the trajectory of resistant TB cases in Germany.
